ERBB2 and breast carcinoma: The group of Liu et al. assessed the expression of several miRNAs selected by literature research via quantitative real-time PCR in serum samples of 83 early HER2+ breast cancer patients receiving a neoadjuvant chemotherapy combined with trastuzumab [68].